Changes in Beneficial Ownership · 4
Rapport Therapeutics, Inc.
RAPPNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-09-23
- Issuer
- Rapport Therapeutics, Inc.
- Issuer CIK
- 0002012593
- Trading symbol
- RAPP
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- Ceesay Abraham
- Reporting owner CIK
- 0001722140
- Relationship
- Director · Officer
- Officer title
- Chief Executive Officer
- Address
- RAPPORT THERAPEUTICS, INC., 99 HIGH STREET, SUITE 2100, BOSTON, MA, 02110
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-09-23 | S · Form 4[F1] | 1,952 | D | 39.0523[F2] | 457,025 | D |
| Common Stock | 2026-09-23 | S · Form 4[F1] | 215 | D | 39.8602[F3] | 456,810 | D |
| Common Stock | 2026-09-23 | S · Form 4[F1] | 43 | D | 41.05 | 456,767 | D |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Direct
Non-derivative holdings
| Security | Amount owned | Ownership | Nature of ownership |
|---|---|---|---|
| Common Stock | 81,729 | I | By Ceesay Family Irrevocable Trust |
| Common Stock | 20,729 | I | By Dorothy Ceesay Irrevocable Trust |
Table key
- I
- Indirect
Footnotes
- F1
- These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026.↩ 1↩ 2↩ 3
- F2
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.54 to $39.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.↩ 1
- F3
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.57 to $40.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.↩ 1
Signature 1
- Signed
- /s/ Troy Ignelzi, Attorney-in-Fact
- Date
- 2026-09-24
Company context
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological and psychiatric disorders. The Company’s founders made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain, which form the basis of Rapport’s RAP technology platform. The platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead investigational drug, RAP-219, which is designed to achieve neuroanatomical specificity through selective targeting of a RAP expressed only in discrete regions of the brain. The pipeline is anchored by the Company’s epilepsy portfolio, including FOS and primary generalized tonic-clonic seizures, as well as bipolar mania. The Company is also advancing additional discovery and preclinical programs leveraging its platform, including in chronic pain and migraine and in hearing and vestibular disorders. Availability of Other Information About Rapport Therapeutics Rapport Therapeutics uses and intends to continue to use its Investor Relations website and LinkedIn (Rapport Therapeutics) as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor